Introducing PanTracer Pro: Now Available

In the evolving landscape of precision oncology, accessing tumor-specific biomarker insights is critical. PanTracer Pro combines comprehensive genomic profiling (CGP) of over 500 cancer-related genes with cancer type-directed ancillary testing*, including IHC and HRD scoring, to provide personalized insights for therapy selection.

We are proud to introduce PanTracer Pro, the latest addition to the PanTracer family, delivering on our promise of robust, simple solutions for therapy selection.

PanTracer Pro reflects NeoGenomics’ ongoing commitment to advancing precision oncology through solutions that empower oncologists and support patient care.

For more information on PanTracer Pro, please reach out to your local sales representative.  

AML Express, with its class-leading turnaround time, delivers a single report that offers a comprehensive NGS-based assessment, providing rapid diagnostic, predictive, or therapeutic information. We don't expect you to put your patients' cancer questions in the hands of just anyone. When it matters, it matters who you ask.

For test information, including specimen requirements and ordering information, visit our website.

Learn more about how HGFR (MET) testing can enhance your lung cancer workflow by visiting our website.

AML Express™ to Launch in New York State

NeoGenomics is pleased to announce that we will be launching our AML Express panel in New York state next week, providing guideline-driven biomarker testing and expedited results to inform patient care.

The c-MET CDx for NSCLC

The c-MET CDx for NSCLC from NeoGenomics is a next-generation IHC assay that delivers precise MET protein measurement, supporting oncologists in selecting patients who could respond to a new targeted treatment.